Canada has approved a generic version of semaglutide, marketed as Ozempic, making it the first G7 country to do so. This approval allows patients to access the medication at significantly lower prices, with costs dropping from C$350 (approximately $250 USD) to under C$100 per month. In contrast, many Americans face exorbitant prices for Ozempic, often exceeding $1,000 monthly, due to extended patent protections that prevent generics from entering the market until 2032. The introduction of generics in Canada is expected to benefit approximately three million Canadians currently using GLP-1 medications, as well as those who previously avoided them due to cost. Experts note that the US patent system has created a significant barrier to access, with ongoing discussions among Americans about obtaining the cheaper Canadian generics. The situation highlights the disparities in drug pricing and availability between Canada and the US, prompting calls for reform in the US patent system to improve access to essential medications.